PHILADELPHIA — Michael Bogda, president of Lannett Co., plans to leave the company to pursue other interests.

Michael Bogda

Lannett, which announced the move late Monday, said that Bogda is slated to depart on June 3.

In February, Lannett said Bogda was leading a team to implement its restructuring plan, focusing on streamlining operations and cost reduction. The plan is part of Lannett’s integration of its acquisition of Kremers Urban Pharmaceuticals.

“Mike spearheaded the integration of our two most recent acquisitions, Kremers Urban Pharmaceuticals and Silarx Pharmaceuticals, as well as a companywide restructuring and cost savings program, which we began implementing earlier this year,” stated Arthur Bedrosian, chief executive officer of Lannett.  “With our path forward firmly developed and well under way, the integration continues to be on track, and our experienced and talented team will assume control of and continue to execute our plan.”

Bogda became president at Lannett in December 2014, joining the generic drug maker from Teva Pharmaceuticals, where he was executive vice president for Americas technical operations, overseeing production, sourcing and supply chain, among other duties.

Before Teva, Bogda held a number of positions of increasing responsibility at Barr Pharmaceuticals, rising to president and chief operating officer of Barr Laboratories. And prior to Barr, he served as vice president of operations for Copley Pharmaceuticals.